AI technologies are rapidly transforming the healthcare and pharmaceutical industries—from drug discovery and experimental process optimization to diagnostic support, clinical practice, and personal health management. Yet these fields must operate under strict regulations while tackling the complexities of life sciences and chemistry to bring new products and services to market.
Preferred Networks (PFN) harnesses the power of computing to predict and simulate molecular properties and biological mechanisms that were once beyond calculation. By applying AI to accelerate research and improve operational processes, PFN supports faster, more accurate, and more efficient innovation in healthcare and life sciences.
P-FEP is a service where PFN uses its in-house supercomputer to undertake binding free energy calculations - a critical component for streamlining drug discovery research. Users only need to prepare their own designed ligand compounds (small molecular compounds that specifically bind to target proteins) enabling them to obtain rapid prediction results for binding free energy calculations.
AUTiv® is a robotic system developed by PFN in collaboration with Chugai Pharmaceutical to reduce the burden on both animals and researchers in biomedical and pharmaceutical experiments. It automates the injection of solutions into the tail vein of laboratory mice—a task that previously required skilled manual operation. AUTiv has received the Roche 3Rs Award and the 2023 Japan Medical AI Association Incentive Award. AUTiv is manufactured by Natsume Seisakusho and marketed by Summit Pharmaceuticals International.
PreferredAI™ is a group of PFN's products and services for solving diverse business challenges across industries.
Talent Scouter: Aptitude assessment through AI avatar interactions, ensuring consistent talent acquisition
Work Suite: AI agent supporting day-to-day operations using company-internal data
Insight Scan: Classification of large text data from reviews and surveys to uncover valuable insights
